iberdomide + R-CHOP-21

**iberdomide + R-CHOP-21** is a novel pharmaceutical combination consisting of the investigational drug **iberdomide** (also known as CC-220) combined with the standard **R-CHOP-21** regimen for first-line treatment of aggressive B-cell lymphoma. - **Iberdomide** is a cereblon E3 ligase modulator (CELMoD) that induces degradation of transcription factors such as Ikaros and Aiolos, leading to immunomodulatory and anti-neoplastic effects. - **R-CHOP-21** is a chemoimmunotherapy regimen comprising rituximab (anti-CD20 monoclonal antibody), cyclophosphamide (alkylating agent), doxorubicin (topoisomerase II inhibitor), vincristine (microtubule inhibitor), and prednisone (glucocorticoid). The goal of combining iberdomide with R-CHOP-21 is to enhance anti-tumor activity in aggressive B-cell lymphoma, building on previous efforts to intensify standard regimens by adding novel agents[9].

Other names

iberdomide + R-CHOPiberdomide/CC-220 plus R-CHOP